Erowid.org: Erowid Reference 6536 : Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA) : Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE

Erowid References Database

Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE. “Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)”. J Med Chem. 1998 Mar 12;41(6):1001-5. <a name="ref">Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE.</a> <a href="/references/6536">"Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)"</a> <i>J Med Chem</i>. 1998 Mar 12;41(6):1001-5.
Text Abstract (this page) Full Text - English (private) Show Articles by Parker MA Marona-Lewicka D Kurrasch D Shulgin AT Nichols DE Article IDs Erowid RefID: 6536 PubMedID: 9526575 Collections Hofmann Collection MDMA Collection All References	Abstract The three isomeric ring-methylated derivatives of the well-known hallucinogen and entactogen MDA (1a) were synthesized and evaluated for pharmacological activity as monoamine-releasing agents and as serotonin agonists. The 2-methyl derivative 2a and the 5-methyl derivative 2b were found to be more potent and more selective than the parent compound in inhibiting [3H]-serotonin accumulation in rat brain synaptosomal preparations. Their activity in vivo was confirmed in rats trained to discriminate serotonin-releasing agents and hallucinogens from saline. The results indicate that compounds 2a,b are among the most potent 5-HT-releasing compounds known and show promise as lead compounds in the search for antidepressant drugs that release serotonin rather than inhibit its uptake.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]